myasthenia myasthenia gravis
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Cross-sectional study (objective 1) Patients with MG: * Patient is legally capable * Definitive diagnosis of MG defined as the presence of a typical history and at least one positive ancillary test, including edrophonium testing, RNS, and serum autoantibodies (anti-acetylcholine receptor [AChR], anti-muscle specific tyrosine kinase [MuSK]). Healthy controls: * Healthy control is legally capable * No diagnosis of MG * Absence of disease that involves eye-muscle function or any other muscle disease Controls with other neuromuscular diseases: * Patient is legally capable * No diagnosis of MG * Definite diagnosis of other neuromuscular disease Controls non-neuromuscular diseases that can cause diplopia: * Patient is legally capable * No diagnosis of MG * No other neuromuscular disease * Definite diagnosis that can cause diplopia * Presence of diplopia Longitudinal study (objective 2) Patients with the clinical suspicion of MG: * Patient is legally capable * MG is in the differential diagnosis * No definitive diagnosis of MG' Neostigmine study (objective 3) Patients who undergo an acetylcholinesterase inhibitor (neostigmine) test within routine clinical care: * Patient is legally capable * MG is in the differential diagnosis * Patient undergoes neostigmine test for diagnostic purposes
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:, * Patients who are legally incapable * Patients who are under the age of 16 * Patients with known vestibulo-cochlear disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The endpoint for objective 1 is the amount of decrement. We will investigate cross-sectionally which cut-off value results in the best combination of sensitivity and specificity by calculating a ROC curve. We will compare this cut-off value with that of Valko et al.. | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. The endpoint for objective 2 is the presence of significant decrement, using the cut-off value established in objective 1 in order to calculate the specificity and sensitivity of the oVEMP test longitudinally. 3. The endpoint for objective 3 is the decrease of decrement. We will study whether decrement decreases after administration of acetylcholinesterase inhibitors (neostigmine test). 4. The endpoint in objective 4 is the reproducibility of decrement in two consecutive measurements in the same subjects. | — |
Countries
Netherlands
Outcome results
None listed